CytomX Therapeutics Inc Total Assets
CytomX Therapeutics Inc total assets. Based on the latest financial reports, CytomX Therapeutics Inc (CTMX) holds total assets worth $381.23 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see market value of CytomX Therapeutics Inc for the company's overall valuation and market capitalisation.
Total Assets of CytomX Therapeutics Inc (2013–2025)
Total assets of CytomX Therapeutics Inc from 2013 to 2025. This chart illustrates how CytomX Therapeutics Inc's total assets have evolved over time, based on quarterly financial data. See CytomX Therapeutics Inc (CTMX) share price today for real-time trading data and today's change.
CytomX Therapeutics Inc - Asset Composition Analysis
CytomX Therapeutics Inc Total Assets Breakdown (December 2025)
CytomX Therapeutics Inc total assets breakdown as of December 2025. CytomX Therapeutics Inc's total assets of $381.23 Million consist of 95.0% current assets and 5.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 8.4% |
| Accounts Receivable | $2.01 Million | 1.3% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $438.00K | 0.3% |
| Goodwill | $949.00K | 0.6% |
Asset Composition Trend (2013–2025)
This chart illustrates how CytomX Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore CytomX Therapeutics Inc short-term liquidity ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: CytomX Therapeutics Inc's current assets represent 95.0% of total assets in 2025, an increase from 65.3% in 2013.
- Cash Position: Cash and equivalents constituted 8.4% of total assets in 2025, down from 61.4% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 18.0% in 2013.
- Asset Diversification: The largest asset category is accounts receivable at 1.3% of total assets.
CytomX Therapeutics Inc Competitors by Total Assets
Key competitors of CytomX Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL
|
Belgium | €37.05 Million |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA
|
USA | $1.14 Billion |
|
Gempharmatech Co. Ltd. A
SHG:688046
|
China | CN¥2.80 Billion |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $481.05 Million |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
|
Sunmax Biotechnology Co Ltd
TWO:4728
|
Taiwan | NT$1.90 Billion |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
CytomX Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 9.36 | 4.20 | 2.42 |
| Quick Ratio | 9.36 | 4.20 | 2.42 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $333.29 Million | $125.40 Million | $141.23 Million |
CytomX Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between CytomX Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.01 |
| Latest Market Cap to Assets Ratio | 3.13 |
| Asset Growth Rate (YoY) | 25.7% |
| Total Assets | $151.57 Million |
| Market Capitalization | $475.02 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values CytomX Therapeutics Inc's assets at a significant premium (3.13x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: CytomX Therapeutics Inc's assets grew by 25.7% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for CytomX Therapeutics Inc (2013–2025)
The table below shows the annual total assets of CytomX Therapeutics Inc from 2013 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $151.57 Million | +25.75% |
| 2024-12-31 | $120.53 Million | -40.27% |
| 2023-12-31 | $201.79 Million | -22.65% |
| 2022-12-31 | $260.89 Million | -23.13% |
| 2021-12-31 | $339.41 Million | -5.37% |
| 2020-12-31 | $358.66 Million | +5.09% |
| 2019-12-31 | $341.28 Million | -25.34% |
| 2018-12-31 | $457.11 Million | +14.95% |
| 2017-12-31 | $397.64 Million | +99.69% |
| 2016-12-31 | $199.13 Million | +0.97% |
| 2015-12-31 | $197.22 Million | +169.93% |
| 2014-12-31 | $73.06 Million | +415.14% |
| 2013-12-31 | $14.18 Million | -- |
About CytomX Therapeutics Inc
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company that focuses on developing potent biologics designed to treat tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell… Read more